Results 131 to 140 of about 3,868 (289)

Presynaptic Congenital Myasthenic Syndromes

Muscle &Nerve, EarlyView.
ABSTRACT Presynaptic congenital myasthenic syndromes (CMS) encompass a large number of rare neurologic disorders caused by impaired release of acetylcholine (ACh) from motor nerve terminals. There are two main groups of presynaptic CMS: one in which the amount of ACh in synaptic vesicles (SV) is diminished and another in which the mechanism of synaptic
Ricardo A. Maselli
wiley   +1 more source

Midodrine and Other Sympathomimetics [PDF]

, 2004
Janice L. Gilden
core   +1 more source

L-Type Ca_v1.3 and HCN Channels Mediate Heart Rate Acceleration by Catecholamines. [PDF]

Circ Res
Torre E, Faure M, Bidaud I, Baudot M, Gaillardon M, Pereira de Vasconcelos W, Laarioui S, Talssi L, Engeland B, Reiken S, Saponaro A, Chen BX, Moroni A, D'Souza A, Isbrandt D, Marks AR, Marx SO, Mesirca P, Mangoni ME.   +18 more
europepmc   +1 more source

The Differing Phenotypes of the Three Most Common Postsynaptic Congenital Myasthenic Syndromes Governed by Their Underlying Molecular Pathogenic Mechanisms

Muscle &Nerve, EarlyView.
ABSTRACT The congenital myasthenic syndromes are rare disorders of impaired signal transmission at the neuromuscular junction. Despite next generation sequencing facilitating the identification of variants in myasthenic‐associated genes, these variants are frequently of unknown significance and the clinical diagnosis can be delayed.
David Beeson
wiley   +1 more source

Cocaine and Other Sympathomimetics [PDF]

, 2010
Rama B. Rao, Robert S. Hoffman
core   +1 more source

Problems associated with the ATC system of drug classification. [PDF]

Naunyn Schmiedebergs Arch Pharmacol
Bindel LJ, Seifert R.
europepmc   +1 more source

How Can We Personalize the Delivery of Onabotulinumtoxin‐A for Patients With Neurogenic Lower Urinary Tract Dysfunction?

Neurourology and Urodynamics, EarlyView.
ABSTRACT Background & Aims Neurogenic lower urinary tract dysfunction (NLUTD) can produce bothersome urinary symptoms, impact quality of life, and in some cases, lead to deterioration of upper urinary tract function. Intradetrusor injection of onabotulinumtoxin‐A (BoNT‐A) is approved for NLUTD in patients who have an inadequate response to or ...
Shirley L. Wang, William I. Jaffe, Ariana L. Smith   +2 more
wiley   +1 more source

Adrenergic drugs (Sympathomimetics) [PDF]

, 2010
Arvind Panwar
core   +1 more source

Fetal Congenital Complete Heart Block: 2 Success Stories Through Multidisciplinary Care. [PDF]

JACC Case Rep
Abdul Ghayum MA, Schermerhorn J, Hancock H, Malloy-Walton L, Olsen S, Vricella L, Brattrud K, Kathol M, France R, Kiaffas M.   +9 more
europepmc   +1 more source

Mirabegron and Intradetrusor Onabotulinumtoxina for Overactive Bladder in Parkinson's Disease: A Systematic Review and Meta‐Analysis

Neurourology and Urodynamics, EarlyView.
ABSTRACT Objective To synthesize the evidence on the efficacy and safety of mirabegron and intradetrusor onabotulinumtoxinA (BoNT‐A) as separate interventions for overactive bladder (OAB) in Parkinson's disease (PD). Methods A systematic review and meta‐analysis with parallel synthesis of two distinct interventions was conducted of randomized and ...
Hussain Arshad, Raiyana Nuha, Shehab Khashaba, David Gillatt, Simon J. G. Lewis   +4 more
wiley   +1 more source